APUS חוב כולל להון Apimeds Pharmaceuticals US
Apimeds Pharmaceuticals (APUS) is developing Apitox biologics to combat sclerosis and osteoarthritis. The market trend on the GURU.Markets platform illustrates the company's expansion strategy, where the individual debt-to-equity ratio stands at 0.14. Revenues are based on the sale of purified bee venom products to clinics treating autoimmune pathologies. Steady sales are driven by growing demand for unique natural components within the emerging anti-inflammatory therapy segment.
פילוחים אנליטיים ודוחות נתונים של חברת Apimeds Pharmaceuticals US (APUS)
This indicator measures the ratio of borrowed funds relative to equity, where the value 0.14 reflects the current level of financial leverage and the risk of a liquidity gap. For Apimeds Pharmaceuticals (APUS), given its monopoly position in bee venom therapy, moderate debt accelerates the scaling of patents, which is clearly tracked via the debt-to-equity coverage ratio.